Blog
RSS FeedPosted by Michael Wonder on 26 Apr 2024
Melphalan flufenamide hydrochloride in combination with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma
25 April 2024 - NICE is unable to make a recommendation on the use of melphalan flufenamide hydrochloride (Pepaxti) in combination ...
Posted by Michael Wonder on 25 Apr 2024
Children and teenagers with an aggressive form of brain cancer set to benefit after NICE recommends new life-extending drug combination treatment
24 April 2024 - A new targeted drug combination treatment, described as a ‘step-change in care’ for children and young ...
Posted by Michael Wonder on 24 Apr 2024
Pembrolizumab in combination with gemcitabine and cisplatin for the first-line treatment of patients with advanced biliary tract cancer
24 April 2024 - NICE is unable to make a recommendation on the use of pembrolizumab (Keytruda) in combination with cisplatin ...
Posted by Michael Wonder on 11 Apr 2024
Children and young adults to benefit after NICE recommends personalised immunotherapy to treat blood cancer be made routinely available on the NHS
11 April 2024 - Innovative CAR-T therapy recommended to treat an aggressive form of leukaemia. ...
Posted by Michael Wonder on 10 Apr 2024
Cabozantinib maleate in combination with nivolumab for the first-line treatment of patients with advanced renal cell carcinoma
10 April 2024 - NICE has published final evidence-based recommendations on the use of cabozantinib maleate (Cabometyx) in combination with ...
Posted by Michael Wonder on 03 Apr 2024
Dostarlimab in combination with platinum-based chemotherapy for the treatment of patients with advanced or recurrent, high microsatellite instability or mismatch repair deficiency endometrial cancer
3 April 2024 - NICE has published final evidence-based recommendations on the use of dostarlimab (Jemperli) in combination with platinum-based ...
Posted by Michael Wonder on 07 Mar 2024
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation
28 February 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 06 Mar 2024
Epcoritamab for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after two or more systemic treatments
6 March 2024 - NICE has published final evidence-based recommendations on the use of epcoritamab (Tepkinly) for the treatment of ...
Posted by Michael Wonder on 06 Mar 2024
NICE publishes final draft guidance on Enhertu after commercial discussions conclude without a price to make it a cost-effective use of NHS resources
6 March 2024 - NICE has published final draft guidance that does not recommend Enhertu (trastuzumab deruxtecan; Daiichi Sankyo) for treating ...
Posted by Michael Wonder on 05 Mar 2024
New treatment option available today for womb cancer
5 March 2024 - A new treatment option given with chemotherapy is recommended for some types of advanced or recurrent ...
Posted by Michael Wonder on 21 Feb 2024
Talazoparib tosylate for the treatment of patients with advanced BRCA mutation positive HER2 negative breast cancer (final guidance)
21 February 2024 - NICE has published final evidence-based recommendations on the use of talazoparib tosylate (Talzenna) for the treatment ...
Posted by Michael Wonder on 10 Feb 2024
Isatuximab in combination with pomalidomide and dexamethasone for the treatment of patients with relapsed and refractory multiple myeloma
9 February 2024 - NICE is reviewing its guidance on the use of isatuximab for the treatment of patients with ...
Posted by Michael Wonder on 07 Feb 2024
Nivolumab with relatlimab for the treatment of patients with unresectable or metastatic melanoma
7 February 2024 - NICE has published final evidence-based recommendations on the use of nivolumab with relatlimab (Opdualag) for the ...
Posted by Michael Wonder on 05 Feb 2024
Selinexor in combination with bortezomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma
2 February 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 01 Feb 2024
Ivosidenib for the treatment of patients with advanced IDH1 R132 mutation positive cholangiocarcinoma after one or more systemic treatments
31 January 2024 - NICE has published final evidence-based recommendations on the use of ivosidenib (Tibsovo) for the treatment of ...